Inclusion Criteria:

        Patient Inclusion:

          -  Patient may have M0 or M1 disease

          -  Confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, as
             evidenced by a serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) and Clear progressive
             disease, as evidenced by a minimum of two rising PSA levels measured at least 7 days
             apart or new clinical or imaging evidence of progressive metastatic disease

          -  Initiating the first or second line treatment for CRPC: including anti- androgens,
             androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy.
             Previous first line CRPC treatments are limited to: First generation anti-androgens
             (bicalutamide, flutamide, or nilutamide) or Sipuleucel-T

          -  Patients may be enrolled within 90 days from the time of decision to treat or within
             90 days of treatment initiation.

          -  Willing and able to complete periodic patient-reported outcome (PRO) questionnaires,
             with or without assistance

          -  Estimated life expectancy of ≥ 6 months

        Caregiver Inclusion:

          -  Meets the definition of an unpaid relative or friend who helps the patient with his or
             her activities of daily living

          -  Willing and able to complete caregiver-reported outcome questionnaires over the course
             of the patient's participation in the study

        Exclusion Criteria:

        Patient Exclusion:

          -  Receiving concomitant treatment for other cancer (excluding basal cell carcinoma,
             squamous cell carcinoma and treatment for hormone sensitive prostate cancer) within 6
             months prior to enrollment.